$ABTI “Stock Rock and Roll” Promoter Rank: 10/25 Alterola Biotech, Inc. Newsletter 4:50:05 PM October 12, 2021

on October 12, 2021 Newsletters and Tags: , , , , , , , , , , with 0 comments

Overall Perfomance for "Stock Rock and Roll"

The following three charts can be used by potential investors to gauge the performance of "Stock Rock and Roll":


186 out of 308 campaigns closed down on first day


79 out of 308 campaigns closed up on first day


43 out of 308 campaigns had no net effect

ABTI Promotional Newsletter

The following is a newsletter released by "Stock Rock and Roll" promoting Alterola Biotech, Inc.


The following newsletter has not been verified for accuracy or completeness.

Don't Miss Our Next Huge Winner...

Text 'PS101' to 67076
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
There is no charge.

Msgdata rates may apply.

Previous Close $1.40


It's time go all in on biotech, and we've just identified an amazing opportunity in a sector that many analysts expect to bounce back hard in the near future.

Please turn your immediate attention to .

ABTI is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary product platform across a broad range of therapeutic areas.

Experts Are Predicting An Epic Biotech Bounce

The IBB edged lower Friday after catching some momentary reprieve in Thursdays trading session as the recent sell-off in speculative trades slowed.

Theres likely more upside in store, at least according to the ETFs technical layout, Miller Tabaks Matt Maley told CNBCs on Thursday.

When you see big downdrafts like weve just seen, thats an opportunity where you can add to those positions, the firms chief market strategist said.

Small-cap biotech companies have the potential advantage of a Food Drug Administration FDA more receptive to cutting-edge and rare diseases therapies, . They are also strengthened by increased patient lobbying and greater willingness by insurers to pay for treatments.

This could be a great entry point for long-term investors and even short-term ones who like to be a little bit more on the active trading side of things.

ABTI Could Have The Most Upside In The Biotech Space

Shares have ABTI have pulled back significantly from their June 23rd high of $3.09, creating a highly attractive entry point for traders looking for a triple-digit upside opportunity.

If you look at the year-to-date chart below, you can see that ABTI has rallied back hard from these levels on three separate occasions, one of which was an over 200% breakout from $1.00 to $3.09 back in June

About Alterola Biotech Inc.

is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary product platform across a broad range of therapeutic areas. The Company has a number of proprietary drug pipeline candidates including cannabinoids, cannabinoid-like molecules and non-cannabinoid molecules, which are under development for a range of indications. ABTI is also focused on producing quality, low cost of goods ingredients for the pharmaceutical, food and cosmetic sectors, from synthetic, biosynthetic and botanical sources. It is also focused on improving the drug delivery of such classes of compounds and has a range of proprietary technologies in development to enhance the delivery and bioavailability of its product portfolio. Geographically the Company has a presence in the UK, Ireland, Netherlands Europe, USA, Australia, and China. If you would like more information about the Company, please visit our website or email our Investor Relations Department at .

Alterola Biotech is a pharma company working with cannabinoid and
cannabinoid-like molecules.

Achieving a low cost of goods for GMP grade API will mean that the company can service high volume indications, as well as orphan indications. To date, due to the high cost of goods, most pharmaceutical companies have focused on low volume high price orphan indications.

Bringing down the cost of goods and improving delivery opens up a much bigger market for other cannabinoid and cannabinoid-like medicines.

The company has three areas of focus.

Pharmaceutical Development

Developing cannabinoid and cannabinoid-like
medicines across a range of indications for humans and animals.

Improved Drug Delivery

Our exclusive license with Nano4M Ltd seeks to utilize the nano-formulation use of nano-formulation technologies to greatly improve the bio-availability of both the cannabinoids and cannabinoid-like molecules.

Low Cost of Goods

Achieving a low cost of goods for GMP grade Active Pharmaceutical Ingredient API means that the company will be able to service high volume indications, as well as orphan indications.

The ABTI Pipeline

New Molecules, LOW-COST Of Goods and Ground Breaking Drug Delivery System

Achieving a low cost of goods for GMP grade API will mean that the company can service high volume indications, as well as orphan indications. To date, due to the high cost of goods, most pharmaceutical companies have focused on low volume high price orphan indications in the cannabinoid sector.

Bringing down the cost of goods and improving delivery opens up a much bigger market for other cannabinoid and cannabinoid-like medicines.

Alterola is in advanced research and development of several new molecules with great potential, details of which will be published as soon as IP is established.


Alterola Biotech Inc. Confirms Key Executive Appointment Joining the Board

The Company is pleased to announce that Mr. Hunter Land Mr. Land has been appointed as a Director of the Company as of September 22, 2021. Mr. Land, aged 37, is concurrently the Vice President of Translational Research USA, having officially joined the company on September 1, 2021.

Mr. Land has more than 16 years of RD expertise across 15 different indications, as well as more than 9 years of cannabinoid-focused research. As an expert in the field of cannabinoid science, he has developed a pipeline of discovery work on over 20 novel cannabinoids and terpenes. Previously, Mr. Land acted as the Sr. Scientific Director, Director of Cannabinoid Research, and scientific spokesperson at Canopy Growth Corporation. Most notably, Mr. Land was GW Pharma's first full time employee within R D in the US, where he co-authored multiple protocols in refractory epilepsy Dravet Syndrome and Lennox-Gastaut Syndrome, Multiple Sclerosis, pain, and was closely involved in the clinical development of Epidiolex FDA approved prescription CBD. Mr. Land acts as the Sr. Scientific Advisor for the National Hockey League Alumni Association in conjunction with NEEKA Brain Health, a board member of Veterinary Cannabis Society, and lectures at the University of Wisconsin. He has been a featured speaker at over 50 scientific conferences, a named inventor on six patent applications, and has over 20 publications. Mr. Land's experience in business spans several countries over 16 years. Occupying senior management and executive positions, his experience encompasses a broad range of knowledge in the sector.

Mr. Land has confirmed to the Company that he has not held directorship in any other listed companies in the last three years, nor has he previously held any positions with the Company. He does not have any relationship with any director, senior management or substantial or controlling shareholders of the Company. As at the date of this announcement, Mr. Land holds no common shares in Alterola at this date, however the Company has given a compensation package which includes certain stock based compensation. Other than as disclosed, Mr. Land does not hold any shares or underlying shares or debentures of the Company or of any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance. The Board is not aware of any matter in relation to the appointment of Mr. Land that is required to be disclosed pursuant to SEC Rules Governing the Listing of Securities on OTC or of any other matter that needs to be brought to the attention of the shareholders of the Company. In addition, Mr. Land has not had any material direct or indirect interest in any Company transactions or proposed transactions over the last two years.

We are extremely excited by the appointment of Hunter, and welcome him to the team for what is likely to be a very interesting few years ahead. Hunter has an impeccable CV, he understands and embraces the aims and objectives of the Alterola team and importantly I believe he looks forward to the freedom provided by our company culture and environment, said Tim Rogers, Chairman. Hunter is the first of our high profile executive appointments for 2021.

Colin Stott, Alterola's COO stated, I'm delighted to welcome Hunter to Alterola and also to the Alterola Board. Hunter brings a wealth of knowledge and experience to Alterola, both in the preclinical and clinical development of cannabis-based and cannabinoid medicines, and his experience will be invaluable in helping us to transition our pipeline candidates from the preclinical phase into clinical development. He is one of few people in the world with practical experience and understanding of how to execute both preclinical studies and clinical trials with cannabinoid-containing development candidates. It is my great pleasure to work with Hunter again.

Alterola Biotech, Inc. acquires ABTI Pharma Ltd. as part of its strategic move into the cannabinoid medicines sector.

The acquisition of ABTI Pharma Ltd. follows Alterola's recent change of strategic direction into the cannabinoid medicines sector, and has resulted in a new management team for the Company.

As part of the acquisition of ABTI Pharma Ltd., the Company now has a number of potential drug development candidates, technologies and associated intellectual property in its portfolio, which will form part of the Company's research and development RD pipeline. This includes potential drug candidates for the treatment of a number of indications, and access to drug delivery technologies, which it believes will be beneficial to the Company's development pipeline. The Company plans to undertake the necessary RD to progress these candidates through the usual regulatory pharmaceutical drug development process.

Alterola's CEO, Mr. Seamus McAuley, said I am delighted that Alterola has now completed the acquisition of ABTI Pharma Ltd. The acquisition reaffirms the Company's intention to develop pharmaceutical medicines with therapeutic potential, which contain cannabinoid and cannabinoid-like molecules.

Details of Alterola's Executive Staff

Mr. Tim Rogers Executive Chairman

Mr. Rogers has lived and worked extensively across the globe for over 30 years. He has an accountancy background, is multi-lingual and has experience with start-up ventures spanning from Singapore, SE Asia, Australia, USA, Canada, and Europe. He has significant experience in pharmaceuticals, agriculture, essential oils cosmetics sectors and strong relationships with distributors across the world.

Mr. Seamus McAuley Chief Executive Officer

Mr. McAuley is a specialist in the commercial strategy, launch and growth of med-tech products and his experience spans a wide variety of sectors and therapeutic markets. A specialist in mergers and acquisitions, he brings a strong analytical, stakeholder management and leadership skills to proactively deliver new opportunities. A highly strategic leader, with an innate focus on innovation and future capability, Mr. McAuley demonstrates a proven capacity and successful results across the commercial environment through strong and focused leadership.

Mr. Colin Stott Chief Operations Officer

Mr. Stott brings over 30 years' experience in preclinical and clinical pharmaceutical development, with specific expertise in the development of botanical medicines, including cannabinoid cannabis-based medicines. Most notably, from 2001, he spent more than 16 years as Director of Research and Development Operations for GW Pharma, where he was directly involved in the development, approval and launch of Epidiolex and Sativex. During his time at GW Pharma, he also managed GW Pharma's discovery and development pipeline and is a named inventor on many of their key patents. From 2017 - 2019, he was Scientific Affairs Director for GW Pharma for their International Division, and was part of the Medical Affairs team responsible for the preparation of the international ex-US launch of Epidiolex.

Prior to his 19-year tenure at GW Pharmaceuticals, Mr. Stott held various roles in clinical research and development across a range of therapeutic areas, including cardiology, oncology, urology, dermatology, metabolic disorders, neurology, hematology, and organ transplantation. He has published over 20 research papers and is a named inventor on 19 international patent applications.

Mr. Dominic Schiller Chief Intellectual Property Officer

Mr. Schiller is a qualified European Patent Attorney, and a specialist in intellectual property law within the cannabinoid pharmaceutical sector. He specializes in building patent portfolios for biotech companies. Most notably, he helped create and secure some of the earliest and most prominent cannabinoid related patents for GW Pharma, helping them establish an IP portfolio comprising claims directed to plants, plant extracts, extraction technology, pharmaceutical formulations, drug delivery and the therapeutic uses of cannabinoids, as well as plant variety rights. He has also served as patent attorney for a number of other pharma biotech companies, securing patents relating to variety of botanically derived and synthesized medicines, formulations and their medical use. Mr. Schiller serves as IP Counsel to the Company.

Global Medical Cannabinoid Market Expected to Reach $44 Billion by 2024

The global cannabis - Cannabinoid market reportedly reached $13.4 Billion in 2018, and it is expected to reach even greater heights in the near future in fact the market is expected to grow at a CAGR of 22.9% during 2019-2024, reaching a value of US$ 44.4 Billion by 2024, according to a research report by IMARC Group. It what's old is new again given the fact that historically, cannabis has been used medicinally for years in ancient Indian, Chinese, Egyptian and Islamic cultures. Nowadays, cannabis finds application in the treatment of a wide range of diseases and symptoms including cancer, chronic pain, depression, arthritis, diabetes, glaucoma, migraines, epilepsy, MS, AIDS, ALS, Alzheimer's, PTSD, Parkinson's, Tourette's, etc. Owing to its therapeutic benefits, cannabis has been approved for medical use in numerous countries, with varying degrees of legal restriction.

Over 100% In Upside Potential From Here

As we mentioned above, ABTI has a history of bullish breakouts.

ABTI has rallied back hard from these levels on three separate occasions, one of which was an over 200% breakout from $1.00 to $3.09 back in June

The Bottom Line

If you are looking to invest in cannabis stocks, you may want to take a closer look at cannabis biotechs like ABTI in particular. Several cannabis biotech firms are generating significant Street support, but we believe ABTI could offer traders the most significant upside.

CBD may not be federally legal in the U.S., but that doesn't mean the market for cannabidiol CBD isn't about to heat up, and for companies like ABTI looking for more growth, producing hemp-based CBD products is an attractive way to get in on the multi-billion dollar hemp and cannabis craze in the U.S.

That being said, we suggest that you start your research on ABTI, and add it to the top of your watchlist immediately

Best Regards,

The StockRockandRoll Team

Don't Miss Our Next Huge Winner...

Text 'PS101' to 67076

to have our Trade Alerts

Delivered Direct

to your Cell Phone.

There is no charge.

Msgdata rates may apply.


Please read our Full Disclaimer

This newsletter is a Paid Advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC, the Financial Marketing Group LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to I or we or our refers to MJ Capital, LLC , the Financial Marketing Group LLC, and PennyStockLocks, LLC.

You are reading this newsletter because you have subscribed via our opt-In signup form on our website. If you have been subscribed by accident, then you may .

By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editors, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.

We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here We do NOT own any shares of the companies mentioned herewithin, nor intend to buy any in the future.

You should read and review, if and to the extent available, any information concerning an advertised company available at the web sites of the U.S. Securities and Exchange Commission the SEC at and the Financial Industry Regulatory Authority the FINRA at We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud at , as well as related information published by the NASD on how to invest carefully. You are responsible for verifying all claims and conducting your own due diligence. You agree and acknowledge that any hyperlinks to the website of 1 an advertised company, 2 the party issuing or preparing the information for the advertised company, or 3 other information contained in our disseminated emails is provided only for your reference and convenience. We are not responsible for the accuracy or reliability of these external sites, nor are we responsible for the content, advertising, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated email or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on us, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink. You also acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser. You acknowledge that you will consult with your own advisers regarding any decisions as to any advertised company.

Our business model is to receive financial compensation to promote public companies. In accordance with Section 17b of the Securities Act of 1933, you are hereby advised that we are being paid on a Cost-Per-Click basis which may exceed a fee of over $1000.00 in cash, from a third party as compensation for the distribution of this advertisement.

We have been compensated as much as ten thousand dollars via bank wire by ACN LLC to conduct a 2-day investor relations advertising and marketing campaign 10122021 to 10132021 for ABTI.

Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.

We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled companys website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, we often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writers communications regarding the profiled companys. You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.

Last 3 Stock Promotions By "Stock Rock and Roll"

Symbol Company Start Date Close Change
FLLLF FEEL FOODS LTD. September 22, 2021 0.220 -3%
XIGMF Xigem Technologies Corporation September 21, 2021 0.170 13%
PAOG PAO Group, Inc. September 15, 2021 0.0026 4%